Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05611593
Other study ID # CSP-001-FOL1
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date October 20, 2022
Est. completion date February 2025

Study information

Verified date March 2024
Source Follicle Pharma Ltd
Contact Solli Brawer
Phone +972747366444
Email info@folliclepharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The CSP-001-FOL1 clinical study is aimed to investigate whether local topical administration of FOL100 lotion will be safe for the patient and will not cause local or systemic skin or other adverse events. It is also aimed at indicating effectiveness as compared with oral Finasteride 1mg. In this non-blinded study, each patient will choose his preferred arm (oral finasteride or FOL100 location). During the study, safety and efficacy will be measured as well as usability.


Description:

The proposed clinical study aims to test the safety, tolerability and usability of FOL100 compared to the commercially available Finasteride 1mg Propecia in male subjects suffering from AA. Study endpoints: Primary Endpoint: Safety-AE(s) & SAE(s) incidence rate. Secondary Endpoint: Tolerability & usability collecting information on safety, tolerability & usability. Exploratory Endpoint: Efficacy 1. Mean change in total, vellus and non-vellus hair count, total hair density, cumulative hair diameter and mean hair thickness in the target region. 2. Global photographic assessments. 3. Subject self-assessment.


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date February 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Written informed consent will be signed by the subject before starting any study related procedures. 2. Male subject between the ages of 18 to 45 years old. 3. Male subject with mild to moderate vertex male-pattern hair loss, classified as grade III vertex to V, according to the modified Norwood/Hamilton Scale. 4. Subject must be willing to maintain normal shampooing habits and products during the study. 5. Fitzpatrick skin phototype classification of I-IV. 6. Subjects will agree to maintain the same haircut and color throughout the study, with no significant changes that will interfere with study objectives, as determined by the investigator. 7. Ability to understand and cooperate with the investigator and to comply with the requirements of the study protocol. Exclusion Criteria: 1. Clinically significant abnormal skin findings on the scalp, which in the opinion of the investigator, could interfere with the aim of the study; in particular, abrasion, actinic keratosis, inflammatory disorders, or any other abnormality. 2. Hair transplant surgery or hair weaving. 3. Clinically significant and active physical illness that could interfere with study objectives or may risk patient safety as determined by the Investigator during screening. 4. Ascertained or presumptive hypersensitivity to the active principle and/or any of the formulation ingredients; history of anaphylaxis to drugs or allergic reactions in general, which in the opinion of the investigator may affect subject safety or the outcome of the study. 5. History of local infections of the skin or subcutaneous tissues of the head within 3 months prior to study enrollment. 6. Clinically significant history of renal, hepatic, gastrointestinal, cardiovascular, respiratory, skin, hematological, endocrine, or neurological diseases, which in the opinion of the investigator may affect subject safety or the outcome of the study. 7. Suspicion of malignancy, including prostate cancer. 8. Subject whose sexual partner(s) is pregnant or plan to become pregnant. 9. Concurrent use of systemic corticosteroids, topical corticosteroids in the area treated in the study, anabolic steroids, or over the counter "hair restorers". 10. Use of any of the following products 1 year for systemic use and 6 months for topical use: minoxidil (topical or oral), zidovudine, cyclosporine, diazoxide, phenytoin, systemic interferon, psoralens, streptomycin, penicillamine ,benoxaprofen, tamoxifen, phenothiazines or cytotoxic agents. 11. Use of oral finasteride or dutasteride, within 18 months prior to enrollment and 6 months prior to enrollment for any topical medication that is considered to affect hair growth. 12. Use of a therapeutic shampoo for hair loss within 1 month prior to enrollment. 13. Light or laser treatment of scalp within 3 months prior to enrollment. 14. Unwilling to undergo a superficial ink marking on the scalp vertex during V0.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOL100
FOL100 lotion
Propecia 1Mg Tablet
Oral Finasteride

Locations

Country Name City State
Israel Rabin Medical Center Petah tikva
Israel Sheba Medical Center Ramat Gan
Israel Sourasky Medical Center Tel Aviv

Sponsors (1)

Lead Sponsor Collaborator
Follicle Pharma Ltd

Country where clinical trial is conducted

Israel, 

Outcome

Type Measure Description Time frame Safety issue
Other Change in hair count Change in total hair count, vellus and non-vellus hair count per cm^2 as assessed by Phototrichogram 28 weeks
Other Change in total hair density Change in total hair density per cm^2 as assessed by Phototrichogram 28 weeks
Other Change in hair thickness Change in cumulative diameter and hair thickness per cm^2 as assessed by Phototrichogram 28 weeks
Other Exploratory Endpoint: Efficacy - self-assess Subject self-assessment by questionnaire 28 weeks
Primary Safety of product application Adverse event reporting (local and general) 28 weeks
Secondary Tolerability & Usability Subject self-assessment by questionnaire 28 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06110377 - MALE HAIR LOSS - Treatment With Dutasteride Mesotherapy x Dutasteride MMP Technique (Injections With Tattoo Machine) Phase 4
Completed NCT03676400 - Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia N/A
Recruiting NCT05938569 - Computer-Assisted Hair Restoration Study Using ARTAS System N/A
Not yet recruiting NCT06326359 - Autologous Stromal Vascular Fraction in Treatment of Male Androgenic Alopecia N/A
Recruiting NCT05426629 - Hydraderm for Androgenic Alopecia Phase 4
Recruiting NCT05827991 - A Clinical Observation of 1565nm Non-ablative Fractional Laser in the Treatment of Androgenic Alopecia N/A
Recruiting NCT05369481 - Comparison Between Efficacy of Topical Sildenafil 2% and Topical Minoxidil 5% in Treatment of Androgenic Alopecia N/A
Not yet recruiting NCT06292533 - Effectiveness of Ultrapulse for the Treatment of Androgenic Alopecia Among Malaysian: A Quasi-experimental Study N/A
Completed NCT02824380 - Pharmacokinetics/ Pharmacodynamics and Safety of DA-4001 in Healthy Male Subjects With Androgenic Alopecia Phase 1
Completed NCT06112782 - Keravive by Hydrafacial for Scalp Health and Enhanced Hair Quality N/A
Completed NCT02594046 - The Effect of Allogeneic Human Adipose Derived Stem Cell Component Extract on Androgenic Alopecia N/A
Recruiting NCT05435625 - Fractional Laser Versus Radiofrequency in Androgenetic Alopecia N/A
Completed NCT05450861 - Effect of the Composition From Fish on Promoting Hair Growth N/A
Completed NCT03506503 - Condensed Nanofat Grafting for Treatment of Androgenetic Alopecia N/A
Completed NCT03467412 - To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin Phase 2
Completed NCT01852487 - Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia N/A
Not yet recruiting NCT03474718 - Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia Early Phase 1
Active, not recruiting NCT02914587 - Computer-Assisted Hair Implantation Using ARTAS System VS Manual Implantation Technique Hair Restoration Study N/A
Completed NCT04341363 - Follicular Revival in Androgenic Alopecia: Evaluating Use of Micro-needling N/A
Completed NCT04450602 - A Study Evaluating the Hair Regrowth Efficacy and Safety of ALRV5XR in Female Subjects With Hair Loss N/A